Two incisions or many? robotic lung cancer surgery put to the test
NCT ID NCT07818135
First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time
Summary
Researchers compare two robotic surgery approaches for removing lung tumors in adults with non-small cell lung cancer. Participants are assigned at random to either biportal surgery, which uses two incisions, or multiportal surgery, which uses several small ports. The study tracks complications, blood loss, pain, hospital stay, and quality of life over 12 months to see which approach works better.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Robotic-assisted thoracic surgery, using either two incisions (biportal) or multiple ports (multiportal)
- What this could lead to
- If one approach proves safer or easier to recover from, it could shape how surgeons plan robotic lung tumor removal and help patients get back on their feet sooner.
- What could go wrong
- Both techniques are already used in practice, so the trial may find little difference between them. Surgery always carries risks such as bleeding, infection, and prolonged air leaks, and results from 80 people may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18 years or older, of any sex. * Non-small cell lung cancer considered clinically resectable, confirmed preoperatively or during surgery. * Candidate for pulmonary resection by robotic thoracic surgery. * Written informed consent. Exclusion Criteria: * Declines participation or cannot provide written informed consent. * Thoracic anatomical abnormalities that preclude or materially affect robotic surgery. * Active thoracic infection. * Surgery not performed by a participating surgeon with comparable experience in biRATS and multiRATS.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital Universitari de Bellvitge
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08907, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans
- Can PET scan signals predict who beats lung cancer with immunotherapy?
- Two-Drug combo takes aim at Hard-to-Treat lung cancer